Moderna : 2024 estimates revised down. A competitive RSV market
>Q2 2024 topped expectations on the top line… - Moderna reported its Q2 2024 results yesterday which prompted a downward adjustment to its 2024 expectations. Q2 results were good in themselves, with revenues ahead of expectations, even though management had pre-guided for c. $ 300m for H1. It therefore comes as no surprise that Spikevax sales fell sharply to $ 184m in Q2. At the operating level, EBIT came in at -$ 1.4bn (vs -$ 1.4bn forecast), impacted in particular b...Moderna is creating a new generation of medicines based on messenger RNA to improve the lives of patients. The company uses its platform to identify and develop new mRNA medicines. When the company identifies a combination of platform technologies or programs across mRNA technologies, delivery technologies, and manufacturing processes that can enable shared product features across multiple potential mRNA medicines, it groups those programs as a modality. The company has created six modalities including prohylactic vaccines; cancer vaccines; intratumoral immuno-oncology; localized regenerative therapeuctics; systemic secreted therapeutics; and systemic intracellular therapeutics.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.